Dive into July’s Topics
Translational Drug Development (TD2)
The Precision Oncology CRO
As we head into the second half of the year, we are excited to showcase our latest highlights in cancer research at TD2. Our goal is to provide you, the researchers, healthcare professionals, and science enthusiasts, with insights into trending topics in oncology and new advancements at TD2 through a selection of videos, blogs, scientific posters, and service spotlights.
VIDEO
Early Steps to Clinical Success: A Discussion with Stephen Gately, PhD, President and CEO of TD2
Clinical trials are expensive and resource-intensive, especially when time is critical. TD2's Clinical Trial Enabling Services streamline the process from late-stage preclinical to the IND process, ensuring rapid study start-up, fast-tracking the first patient in, and reducing time in trial initiation for efficiency and cost-effectiveness.
SERVICE SPOTLIGHT
ADC Therapeutic Development Toolbox
TD2 is a scientifically driven CRO specializing in developing novel cancer treatments, including antibody drug conjugate (ADC) therapies. We provide comprehensive services from preclinical testing to early phase clinical trials, equipping biotech and pharmaceutical companies with the tools and expertise to advance their ADC candidates from discovery to clinical evaluation.
BLOG
Top Trends in ADC Drug Development
Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, combining monoclonal antibodies with potent chemotherapeutic agents to precisely target and eliminate cancer cells. As the field progresses, several key trends are shaping the future of ADC development.
Translational Oncology Services
Learn more about TD2's Clinical Trial Management and Regulatory Support Services here .